Last reviewed · How we verify
Nivolumab plus Platinum Doublet Chemotherapy
Nivolumab plus Platinum Doublet Chemotherapy, marketed by Galvanize Therapeutics, Inc., holds a significant position in the oncology market with a key composition patent expiring in 2028. The combination therapy leverages the synergistic effects of immunotherapy and chemotherapy, providing a robust treatment option for patients. The primary risk lies in the patent expiry in 2028, which could lead to increased competition from generic and biosimilar products.
At a glance
| Generic name | Nivolumab plus Platinum Doublet Chemotherapy |
|---|---|
| Also known as | Carboplatinum, Cipsplatin, Pemetrexed, Gemcitabine, Paclitaxel |
| Sponsor | Galvanize Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer (PHASE3)
- Repositioning Immunotherapy in VetArans With Lung Cancer (PHASE2)
- Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy (PHASE2)
- A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
- An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer (PHASE2)
- Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer (PHASE2)
- A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) (PHASE3)
- An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: